SHANGHAI, March 29 (Reuters) – China’s Hansoh Pharmaceutical Group, a Roche partner, reported a 27% rise in annual profit on Sunday, beating market expectations and boosted by income from innovative medicines and business development deals.
The specialist in oncology, anti-infective, central nervous system disease, metabolic disease and autoimmune disease drugs has expanded licensing deals and developed innovative medicines amid Beijing’s centralised bulk buying programmes, which have squeezed generic drug revenues.
Hansoh said net profit for the 2025 fiscal year that ended December 31 came in at 5.56 billion yuan ($804.44 million), well above a consensus forecast of 4.97 billion yuan in estimates compiled by LSEG.
Revenue for the year jumped 22.6% to 15.03 billion yuan, the company said.
In October, Hansoh signed a licence agreement worth up to $1.45 billion with Roche for an investigational treatment of colorectal cancer and other solid tumours.
The deal was a part of a string of new licensing agreements last year with other overseas drugmakers including the Swiss arm of India’s Glenmark Pharmaceuticals and Regeneron Pharmaceuticals.
($1 = 6.9116 Chinese yuan renminbi)
(Reporting by Andrew Silver and Ju-min Park, editing by Susan Fenton)
Comments